Sectors
SYRE
Spyre Therapeutics, Inc.
100.22
1 x 100.18
1 x 100.46
bid
ask
-
2.48
2.41%
10:07 AM
timesize
| Ytd | 205.92% | |
| 1y | 507.76% |
99.11
day range
102.39
14.51
52 week range
105.09
| Open | 102.39 | Prev Close | 102.70 | Low | 99.11 | High | 102.39 | Mkt Cap | 6.20B |
| Vol | 52.96K | Avg Vol | 1.35M | EPS | -2.08 | P/E | -49.37 | Forward P/E | -31.24 |
| Beta | 3.02 | Short Ratio | 7.57 | Inst. Own | 93.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 83.48 | 200-d Avg | 49.10 | 1yr Est | 103.93 |
| Income Statement | |||
| Operating Expenses | 45.64M | ||
| Research and Development Expense | 60.41M | ||
| Selling, General and Administrative Expense | 15.23M | ||
| Operating Income | -45.64M | ||
| Net Income | -69.00M | ||
| Net Income Common Stock | -69.00M | ||
| Net Income Common Stock (USD) | -69.00M | ||
| Consolidated Income | -69.00M | ||
| Earnings per Basic Share | -0.74 | ||
| Earnings per Basic Share (USD) | -0.74 | ||
| Earnings per Diluted Share | -0.74 | ||
| Earning Before Interest & Taxes (EBIT) | -69.00M | ||
| Earning Before Interest & Taxes (USD) | -69.00M | ||
| Weighted Average Shares | 78.55M | ||
| Weighted Average Shares Diluted | 78.55M | ||
| Balance Sheet | |||
| Cash and Equivalents | 97.19M | ||
| Cash and Equivalents (USD) | 97.19M | ||
| Investments | 644.28M | ||
| Investments Current | 644.28M | ||
| Current Assets | 763.95M | ||
| Total Assets | 763.95M | ||
| Current Liabilities | 85.16M | ||
| Total Liabilities | 93.14M | ||
| Accumulated Retained Earnings (Deficit) | -1.20B | ||
| Accumulated Other Comprehensive Income | -767.00K | ||
| Shareholders Equity | 670.81M | ||
| Shareholders Equity (USD) | 670.81M | ||
| Liabilities Non-Current | 7.98M | ||
| Trade and Non-Trade Payables | 5.74M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 12.26M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 11.46M | ||
| Net Cash Flow - Business Acquisitions and Disposals | 30.00M | ||
| Issuance (Purchase) of Equity Shares | 12.43M | ||
| Net Cash Flow from Investing | 56.58M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 26.58M | ||
| Net Cash Flow from Operations | -57.37M | ||
| Share Based Compensation | 12.81M | ||